A microfluidic chip is configured to determine DILI parameters. The microfluidic chip includes a cell chamber hosting a tissue culture comprising liver tissue; a reoxygenation chamber configured to add oxygen to a fluid media; a fluid loop configured to recirculate the fluid media through the cell chamber and the reoxygenation chamber and supply oxygenated fluid media to the tissue culture; and an oxygen sensor configured to measure an oxygen concentration within the fluid media. The microfluidic chip includes a controller configured to perform operations including recirculating the fluid media in the fluid loop, the fluid media comprising a drug dose; obtaining measurements of the oxygen concentration at a sequence of time points during recirculating; and determining, based on the measured oxygen concentration, at least one physiologic parameter value of the tissue culture that describes a clinical test metric describing a damage level to the tissue culture.

Disclosed are: a kit and a method for diagnosing or monitoring a liver disease, comprising a detection reagent for one or more markers of cytosolic aspartate aminotransferase (cAST) and mitochondrial aspartate aminotransferase (mAST) as biomarkers in a biological sample; and an antibody used for the detection. Compared to the conventional enzyme activity measurement method, the method according to the present application can more accurately measure diagnosis or prognosis of a liver disease with high sensitivity through measurement of the amount of mAST or cAST present in the biological sample, in particular, in a blood sample.

Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A(SEQ ID NO.1) is determined.

A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

A human hepatoma cell line is HLCZ01 cell line which has been deposited in the China Center for Type Culture Collection (CCTCC), and having Accession (deposit) No. is CCTCC NO: C201309. The human hepatoma cell line HLCZ01 is used as a cell model supporting said hepatitis viruses infection and is used to establish an animal model for supporting virus infection, wherein said human hepatoma cell line HLCZ01 is also used for preparation, screening and evaluating anti-hepatitis virus drugs, anti-tumor drugs, and used for manufacturing artificial liver.

A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

This invention describes a cross-sectional study that examines the trends of long-term complications, particularly the incidence of type 2 diabetes mellitus (T2D), in the Saudi population following SARS-COV-2 infection and vaccination. The study collected blood samples from 203 healthy blood donors and analyzed various parameters, including HbA1c, liver function tests, kidney function tests, and lipid profiles. The results showed a significant increase in HbA1c, urea, creatinine, alkaline phosphatase, lactate dehydrogenase, and triglycerides among diabetic patients compared to non-diabetic individuals. Notably, individuals with blood group O had the highest incidence of T2D. These findings suggest that SARS-COV-2 infection and vaccination are associated with the worsening of T2D symptoms and highlight the need for large-scale studies to understand the long-term metabolic complications of the COVID-19 pandemic, aiming to develop effective prevention and management strategies.

The present disclosure relates to acetaminophen protein adducts and methods of diagnosing acetaminophen toxicity using the acetaminophen protein adducts.